The observational evidence for IL‐6 and future ASCVD risk goes hand in hand with what has been reported for hsCRP, which is not surprising since they both are part of the NLRP3 (NOD [nucleotide oligomerization domain], LRR [leucine‐rich repeat] and PYD [pyrin domain]‐containing protein 3) inflammasome pathway. Here, IL6 is linked to atherosclerosis.